However, there have been a number of developments in recent years, including approval of two biologic therapies for SLE: belimumab to neutralize B-cell activating factor (BAFF) (24) and anifrolumab which antagonizes the type I interferon receptor (IFNARI) (25). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.